Abstract
Medullary thyroid carcinoma with distant metastases is generally incurable, with 20% overall survival at 10 years. The treatment goal is palliative. Chemotherapy has a limited role, with low response rates and high toxicities with the different regimens. Here, we report the case of 64-year-old man with metastatic medullary thyroid carcinoma in progression after primary treatment with cisplatin-doxorubicin. The patient received capecitabine 2000 mg/m total per day x 14 days followed by 1-week rest. He received 41 cycles, and presented prolonged and objective tumor response (30 months), without any toxicity.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antimetabolites, Antineoplastic / adverse effects
-
Antimetabolites, Antineoplastic / therapeutic use*
-
Antineoplastic Agents / therapeutic use
-
Capecitabine
-
Carcinoma, Medullary / drug therapy*
-
Cisplatin / therapeutic use
-
Deoxycytidine / adverse effects
-
Deoxycytidine / analogs & derivatives*
-
Deoxycytidine / therapeutic use
-
Doxorubicin / therapeutic use
-
Fluorouracil / adverse effects
-
Fluorouracil / analogs & derivatives*
-
Fluorouracil / therapeutic use
-
Humans
-
Male
-
Middle Aged
-
Neoplasm Metastasis
-
Palliative Care
-
Thyroid Neoplasms / drug therapy*
-
Treatment Outcome
Substances
-
Antimetabolites, Antineoplastic
-
Antineoplastic Agents
-
Deoxycytidine
-
Capecitabine
-
Doxorubicin
-
Cisplatin
-
Fluorouracil